Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Liabilities from Discontinued Operations (2023)

Seres Therapeutics (MCRB) has disclosed Liabilities from Discontinued Operations for 1 consecutive years, with 66922000.0 as the latest value for Q4 2023.

  • Quarterly Liabilities from Discontinued Operations changed N/A to 66922000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was 66922000.0 through Dec 2023, changed N/A year-over-year, with the annual reading at 66922000.0 for FY2023, N/A changed from the prior year.
  • Liabilities from Discontinued Operations hit 66922000.0 in Q4 2023 for Seres Therapeutics.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 66922000.0 in Q4 2023 to a low of 66922000.0 in Q4 2023.